Back to top
more

Certara (CERT)

(Delayed Data from NSDQ)

$11.26 USD

11.26
3,476,373

+1.73 (18.15%)

Updated Aug 7, 2025 03:59 PM ET

After-Market: $11.08 -0.18 (-1.60%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Certara, Inc. (CERT) Q2 Earnings Miss Estimates

by Zacks Equity Research

Certara (CERT) delivered earnings and revenue surprises of -30.00% and +0.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Eton Pharmaceuticals (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Certara, Inc. (CERT) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Certara (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of +26.83% and +15.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Do Options Traders Know Something About Certara Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to CERT stock based on the movements in the options market lately.

Zacks Equity Research

Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Certara (CERT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Harshit Gupta headshot

VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait?

by Harshit Gupta

Veeva Systems gains momentum as strong earnings, Vault CRM growth, and new AI tools reinforce its life sciences edge.

Indrajit Bandyopadhyay headshot

Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS?

by Indrajit Bandyopadhyay

DOCS is leaning on AI tools like Doximity GPT to fuel growth after a strong FY25, but monetization remains early-stage.

Zacks Equity Research

Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Certara (CERT) delivered earnings and revenue surprises of 7.69% and 0.01%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Certara, Inc. (CERT) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Certara (CERT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Certara (CERT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Certara (CERT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?

by Zacks Equity Research

Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Certara, Inc. (CERT) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Certara (CERT) delivered earnings and revenue surprises of 15.38% and 0.68%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

HPQ Set to Report Q1 Earnings: What's in the Cards for the Stock?

by Zacks Equity Research

HP's first-quarter 2025 results are likely to reflect gains from traction in its AI-based computing and latest gaming products.

Zacks Equity Research

Agilent to Report Q1 Earnings: What's in the Cards for the Stock?

by Zacks Equity Research

A's fiscal first-quarter performance is likely to have been influenced by higher expenses, increased CapEx and the Lunar New Year timing shift.

Zacks Equity Research

Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Bio-Rad Laboratories (BIO) and Certara, Inc. (CERT) have performed compared to their sector so far this year.

Zacks Equity Research

Certara, Inc. (CERT) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Certara (CERT) delivered earnings and revenue surprises of 18.18% and 0.92%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Certara (CERT) delivered earnings and revenue surprises of -36.36% and 1.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Certara, Inc. (CERT) Q1 Earnings Meet Estimates

by Zacks Equity Research

Certara (CERT) delivered earnings and revenue surprises of 0% and 2.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Puma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Puma Biotechnology (PBYI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Certara, Inc. (CERT) Lags Q4 Earnings Estimates

by Zacks Equity Research

Certara, Inc. (CERT) delivered earnings and revenue surprises of -18.18% and 1.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Certara, Inc. (CERT) Q3 Earnings Meet Estimates

by Zacks Equity Research

Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 0.45%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Options Traders Betting on a Big Move in Certara (CERT) Stock?

by Zacks Equity Research

Investors need to pay close attention to Certara (CERT) stock based on the movements in the options market lately.